Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a Study to Evaluate the Safety and Tolerability of OCR-002 (Ornithine Phenylacetate) in the Treatment of Patients With Acute Liver Failure/Severe Acute Liver Injury

NCT01548690 is registered in ClinicalTrials.gov with William Lee as lead sponsor.

NCT NCT01548690
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01548690 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a Study to Evaluate the Safety and Tolerability of OCR-002 (Ornithine Phenylacetate) in the Treatment of Patients With Acute Liver Failure/Severe Acute Liver Injury
Lead sponsor
William Lee
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2012
Completion date
February 23, 2017
Enrollment
47 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

acute liver failure, acute liver injury